Answers are grounded in this paper and cite their sources.
A bill passed by the Senate would sharply curtail the FDA’s oversight of access to investigational drugs. Although its impact would probably be limited, the motivation behind it threatens to weaken the FDA’s ability to pursue its public health mission.
No takes yet. Share an insight, caveat, or question.
Joffe et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: